Boceprevir and Telaprevir in the Management of Hepatitis C Virus-Infected Patients

被引：71

作者：

Butt, Adeel A. ^{[1
,2
,3
]}

Kanwal, Fasiha ^{[4
,5
]}

机构：

[1] Univ Pittsburgh, Sch Med, Div Infect Dis, Dept Med, Pittsburgh, PA 15213 USA

[2] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA

[3] Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA

[4] St Louis Univ, Sch Med, St Louis Vet Affairs Med Ctr, St Louis, MO 63103 USA

[5] St Louis Univ, Sch Med, Dept Med, Div Gastroenterol & Hepatol, St Louis, MO 63103 USA

来源：

CLINICAL INFECTIOUS DISEASES | 2012年 / 54卷 / 01期

关键词：

PROTEASE INHIBITOR; ANTIVIRAL THERAPY; PLUS RIBAVIRIN; INTERFERON; RESISTANCE;

D O I：

10.1093/cid/cir774

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Recent approval of direct-acting antiviral agents (DAAs) against hepatitis C virus (HCV) offers a major advance in the management of HCV infection. These DAAs, boceprevir and telaprevir, when given with pegylated interferon alfa (Peg-IFN) and ribavirin (RBV), result in a much higher sustained virologic response rate compared with Peg-IFN and RBV. The DAA-containing regimens are approved for HCV genotype 1 infection in HCV treatment-naive and HCV treatment-experienced patients. In this review, we present an overview of pharmacology, efficacy, adverse events, and emergence of resistance-associated variants with the use of these agents. As with all drugs, especially newly approved drugs, clinicians must consult the package insert for detailed prescribing information, list of all reported adverse events, contraindications, and drug interactions.

引用

页码：96 / 104

页数：9

共 21 条

[1] Sustained Virological Response Reduces Incidence of Onset of Type 2 Diabetes in Chronic Hepatitis C [J].

Arase, Yasuji ;

Suzuki, Fumitaka ;

Suzuki, Yoshiyuki ;

Akuta, Norio ;

Kobayashi, Masahiro ;

Kawamura, Yusuke ;

Yatsuji, Hiromi ;

Sezaki, Hitomi ;

Ilosaka, Tetsuya ;

Hirakawa, Miharu ;

Ikeda, Kenji ;

Kumada, Hiromitsu .

HEPATOLOGY, 2009, 49 (03) :739-744

[2] Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection [J].

Bacon, Bruce R. ;

Gordon, Stuart C. ;

Lawitz, Eric ;

Marcellin, Patrick ;

Vierling, John M. ;

Zeuzem, Stefan ;

Poordad, Fred ;

Goodman, Zachary D. ;

Sings, Heather L. ;

Poordad, Fred ;

Goodman, Zachary D. ;

Sings, Heather L. ;

Boparai, Navdeep ;

Burroughs, Margaret ;

Brass, Clifford A. ;

Albrecht, Janice K. ;

Esteban, Rafael .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (13) :1207-1217

[3] Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3•4A protease inhibitors in treatment-naive subjects [J].

Bartels, Doug J. ;

Zhou, Yi ;

Zhang, Eileen Z. ;

Marcial, Michelle ;

Byrn, Randal A. ;

Pfeiffer, Thomas ;

Tigges, Ann M. ;

Adiwijaya, Bambang S. ;

Lin, Chao ;

Kwong, Ann D. ;

Kieffer, Tara L. .

JOURNAL OF INFECTIOUS DISEASES, 2008, 198 (06) :800-807

[4] Prospective multicenter study of eligibility for antiviral therapy among 4,084 US veterans with chronic hepatitis C virus infection [J].

Bini, EJ ;

Bräu, N ;

Currie, S ;

Shen, H ;

Anand, BS ;

Hu, KQ ;

Jeffers, L ;

Ho, SB ;

Johnson, D ;

Schmidt, WN ;

King, P ;

Cheung, R ;

Morgan, TR ;

Awad, J ;

Pedrosa, M ;

Chang, KM ;

Aytaman, A ;

Simon, F ;

Hagedorn, C ;

Moseley, R ;

Ahmad, J ;

Mendenhall, C ;

Waters, B ;

Strader, D ;

Sasaki, AW ;

Rossi, S ;

Wright, TL .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (08) :1772-1779

[5] Hepatitis C treatment completion rates in routine clinical care [J].

Butt, Adeel A. ;

McGinnis, Kathleen A. ;

Skanderson, Melissa ;

Justice, Amy C. .

LIVER INTERNATIONAL, 2010, 30 (02) :240-250

[6] Effect of Hepatitis C Virus and Its Treatment on Survival [J].

Butt, Adeel A. ;

Wang, Xiaoqiang ;

Moore, Charity G. .

HEPATOLOGY, 2009, 50 (02) :387-392

[7] Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. [J].

Fried, MW ;

Shiffman, ML ;

Reddy, KR ;

Smith, C ;

Marinos, G ;

Goncales, FL ;

Haussinger, D ;

Diago, M ;

Carosi, G ;

Dhumeaux, D ;

Craxi, A ;

Lin, A ;

Hoffman, J ;

Yu, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) :975-982

[8] The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus [J].

Gentile, Ivan ;

Carleo, Maria Aurora ;

Borgia, Federico ;

Castaldo, Giuseppe ;

Borgia, Guglielmo .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 (01) :151-159

[9] Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C -: A randomized study of treatment duration and ribavirin dose [J].

Hadziyannis, SJ ;

Sette, H ;

Morgan, TR ;

Balan, V ;

Diago, M ;

Marcellin, P ;

Ramadori, G ;

Bodenheimer, H ;

Bernstein, D ;

Rizzetto, M ;

Zeuzem, S ;

Pockros, PJ ;

Lin, A ;

Ackrill, AM .

ANNALS OF INTERNAL MEDICINE, 2004, 140 (05) :346-355

[10] Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection [J].

Jacobson, Ira M. ;

McHutchison, John G. ;

Dusheiko, Geoffrey ;

Di Bisceglie, Adrian M. ;

Reddy, K. Rajender ;

Bzowej, Natalie H. ;

Marcellin, Patrick ;

Muir, Andrew J. ;

Ferenci, Peter ;

Flisiak, Robert ;

George, Jacob ;

Rizzetto, Mario ;

Shouval, Daniel ;

Sola, Ricard ;

Terg, Ruben A. ;

Yoshida, Eric M. ;

Adda, Nathalie ;

Bengtsson, Leif ;

Sankoh, Abdul J. ;

Kieffer, Tara L. ;

George, Shelley ;

Kauffman, Robert S. ;

Zeuzem, Stefan .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (25) :2405-2416

← 1 2 3 →